Alert detail
FDA Approval: NDA 220482 — Type 1 - New Molecular Entity
Policy ID: FDA-NDA220482Specialty: Multi-specialtyAdded: 6/5/2026Effective: May 29, 2026billing update
What changed
New IV sedation agent Cypsedo enters Part B; watch for new J-code.
Who’s affected: Multi-specialty billing teams · Effective: May 29, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.